Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells.

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Endothelial monocyte-activating polypeptide-II (EMAP-II) is a tumor-derived cytokine.
• EMAP-II influences endothelial cell function and gene expression.
• Understanding EMAP-II's molecular targets is crucial for cancer research.

Purpose of the Study:

• To investigate gene expression changes in human umbilical vein endothelial cells (HUVEC) induced by EMAP-II.
• To identify specific genes modulated by EMAP-II and elucidate their functional roles.
• To explore the involvement of the Downregulated in Ovarian Cancer 1 (DOC1) gene in EMAP-II's effects.

Main Methods:

• Microarray (MA) analysis of HUVEC treated with EMAP-II for various durations (0.5-8 hours).
• Validation of differentially expressed genes using real-time reverse transcription polymerase chain reaction (RT-PCR).
• Gene silencing of DOC1 using small interfering RNA (siRNA) to assess its role.

Main Results:

• EMAP-II treatment resulted in significant gene expression changes (<0.5 and >2 fold) for 69 genes, primarily occurring early.
• RT-PCR confirmed the specificity and consistency of MA findings in HUVEC compared to human fibroblasts.
• Silencing DOC1 abolished EMAP-II-stimulated DOC1 expression and reversed EMAP-II's modulatory effects on four other genes.

Conclusions:

• EMAP-II induces early and specific gene expression changes in HUVEC.
• DOC1 plays a significant role in mediating EMAP-II's effects on endothelial cells, potentially through cytoskeletal remodeling.
• These findings highlight DOC1 as a key mediator in EMAP-II-induced endothelial cell responses.